Questions over the efficacy of Vytorin and Zetia could prompt a sharp pullback on first- and second-line use of the drug, according to a survey of physicians by GfK Market Measures, but docs are taking a wait-and-see approach with the drugs and remain open to new data. The study found general and family practitioners to be most wary of the drugs, with those respondents reporting they will switch upwards of 40% of their patients on Vytorin and Zetia to other therapies over the next few months. The survey found that physicians are counseling patients to wait until their next visit to talk about alternatives.
Pages to are hidden for
"GfK forecast: sharp decline in Vytorin, Zetia"Please download to view full document